Déjà vu: Stimulating open drug discovery for SARS-CoV-2.

Ekins S, Mottin M, Ramos PRPS, Sousa BKP, Neves BJ, Foil DH, Zorn KM, Braga RC, Coffee M, Southan C, Puhl AC, Andrade CH

Drug Discov Today 25 (5) 928-941 [2020-05-00; online 2020-04-19]

In the past decade we have seen two major Ebola virus outbreaks in Africa, the Zika virus in Brazil and the Americas and the current pandemic of coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). There is a strong sense of déjà vu because there are still no effective treatments. In the COVID-19 pandemic, despite being a new virus, there are already drugs suggested as active in in vitro assays that are being repurposed in clinical trials. Promising SARS-CoV-2 viral targets and computational approaches are described and discussed. Here, we propose, based on open antiviral drug discovery approaches for previous outbreaks, that there could still be gaps in our approach to drug discovery.

Type: Review

PubMed 32320852

DOI 10.1016/j.drudis.2020.03.019

Crossref 10.1016/j.drudis.2020.03.019

pii: S1359-6446(20)30145-8
pmc: PMC7167229


Publications 7.1.2